AR and neoplasm: While the current recommendations for molecular diagnostics with regards to the primary tumor diagnosis are weak, there are indeed several clearer recommendations when systemic therapy is planned: AR in SDC and NTRK fusion in MASC; AR, HER2neu, and NTRK fusion may be offered for non-AdCC; tumor mutational burden (TMB), microsatellite instability (MSI) prior to checkpoint inhibition; next-generation sequencing (NGS) for tumor types with low prevalence.